Lost Money in Athira Pharma, Inc.?

OAKLAND, Calif.--(BUSINESS WIRE)--Athira Pharma, Inc. shares plunged nearly 39% on Friday, June 18, 2021 after the company reported that it was placing president and CEO Leen Kawas on leave, pending a board review of "actions" stemming from Dr. Kawas's work as a doctoral student. Gibbs Law Group is investigating a potential Athira Class Action Lawsuit on behalf of investors who lost money in Athira Pharma, Inc. (NASDAQ: ATHA).

To speak with an attorney regarding this class action lawsuit investigation, click here or call (888) 410-2925.

On Thursday, June 17, 2021, neurological drug company Athira Pharma announced it was placing its president and CEO Leen Kawas on leave while its board formed an independent special committee to review her doctoral research from her time at Washington State University. The school opened its own investigation into "potential research misconduct" by Dr. Kawas the next day. According to Barron's, Athira was founded by Kawas and colleagues from Washington State University based on the research she and others did there.

More on EntSun News

• Voices for Humanity Featuring Pastor Jeffrey Mack's Mission of Peace Wins Gold at Viddy Awards
• Hunter AKA Mark E. Hunter Is Off and Running with 2026 New Music and Tour
• International Law Group Expands Emergency Immigration Consultations for Somali Minnesotans Amid ICE Actions
• Epic Pictures Group Sets North American Release Date for the Thriller THE HUNTSMAN
• Premium Bail Bonds Proudly Sponsors BOFAB BBQ Team at the 2026 Lakeland Pigfest

The Seattle Times reports that online commenters had previously raised concerns about her lab result images on PubPeer, a forum featuring discussions on scientific papers. One commenter, Dr. Elisabeth Bik, told The Seattle Times some results looked like they may have been "photoshopped."

According to Barron's, a Stifel analyst addressed the potential impact to the company in a note, stating: "The scientific hypothesis behind Athira came out of the work [that] Dr. Kawas did in graduate school so there is risk here that whatever comes out of this investigation could have clear negative implications for how we/investors view the asset, and/or management credibility."

Following this news, Athira's stock price dropped nearly 39% at the close of June 18, 2021, causing significant harm to investors.

What Should Athira Investors Do?

If you invested in Athira, visit our website or contact our securities team directly at (888) 410-2925 to discuss how you may be able to recover your losses. Our investigation concerns whether Athira Pharma, Inc. has violated federal securities laws by providing false or misleading statements to investors.

More on EntSun News

• UK Financial Ltd Receives Recognition In Platinum Crypto Academy's "Cryptonaire Weekly"
• P-Wave Press Announces Pushing the Wave 2024 by L.A. Davenport
• Preston Dermatology & Skin Surgery Center Wins Gold and Bronze in Prestigious Annual DIAMOND Awards
• David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District
• Breaking My Music - First in the New Workbook Series

About Gibbs Law Group

Gibbs Law Group represents investors throughout the country in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world's largest corporations, and our attorneys have received numerous honors for their work, including "Best Lawyers in America," "Top Plaintiff Lawyers in California," "California Lawyer Attorney of the Year," "Class Action Practice Group of the Year," "Consumer Protection MVP," and "Top Women Lawyers in California."

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

---

Show All News | Report Violation